Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

Zealand Pharma repurchased 325,000 shares for DKK 90.6 million during September 14-18 under its DKK 1.3 billion buyback program. Total purchases have reached 3.625 million shares for DKK 1.089 billion, leaving approximately DKK 211.1 million of authorized capacity before the program's October 31, 2026 deadline. The company now holds 4.496 million treasury shares, equal to 6.28% of share capital.

Analysis

The remaining authorization implies a mechanical bid through the October 31 deadline, but the more relevant signal is capital-allocation discipline: repurchases at prices materially below the program’s historical average reduce the effective share count at a lower cost. With treasury stock already meaningful, any subsequent cancellation or use in employee compensation will determine whether the buyback becomes durable EPS accretion rather than merely an offset to dilution. For a clinical-stage obesity name, however, the valuation driver remains pipeline probability rather than a modest near-term reduction in float.

Near term, ZEAL may benefit from improved trading support and tighter available float, particularly during low-liquidity sessions; this is not a fundamental catalyst and should fade once the mandate ends. The key 1-3 month risk is an “end-of-buyback” air pocket if discretionary demand does not replace the program’s daily purchases. Over 6-18 months, the buyback is constructive only if management retains sufficient net cash to fund pivotal obesity/metabolic programs without returning to the equity market at a discount.

The contrarian read is that the recent purchase pace reflects execution against a pre-set mandate, not new management information on clinical value. Investors should avoid treating the reported average purchase price as a valuation floor. Watch for cash-balance guidance, trial timelines, and any indication that repurchases are being funded at the expense of development spending; those would matter far more than weekly transaction disclosures. Danske Bank earns execution economics but the activity is too small relative to its broader earnings base to support a standalone DANSKE trade.

Key Decisions for Investors

• Maintain ZEAL only as a catalyst-driven biotech exposure; do not add solely on the buyback. Reassess after program completion on October 31, when removal of the mechanical buyer can reveal underlying demand.
• For an existing ZEAL long, consider trimming 15-25% into buyback-supported strength and retain core exposure only if cash runway covers the next material clinical readout without equity financing; a downward revision to runway or R&D guidance falsifies the capital-return thesis.
• Set a post-program liquidity alert: if ZEAL underperforms the XBI by more than 10% in the two weeks after October 31 without a company-specific clinical development, treat that as evidence the repurchase was the marginal buyer and reduce exposure.
• No standalone DANSKE position: monitor only for execution-quality or mandate-extension disclosures, neither of which is likely to be material to bank earnings.